ENTA vs PATH
Enanta Pharmaceuticals Inc (ENTA) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Enanta Pharmaceuticals Inc (ENTA) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ENTA revenue for 2025-09-30 was $65.3M. Net income was -$81.9M. Revenue was down 3.4% from 2024-09-30 to 2025-09-30. ENTA currently screens at market cap $328.0M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ENTA currently screens at market cap $328.0M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ENTA and PATH stock pages for the full models.
Not investment advice.